Company profile CRSP
CRISPR Therapeutics AG
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad ran...ge of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Show More
After 34 days of this quarter the interest is at 218.0. Based on that we can calculate that during remaining 58 days it will total up to 590.0. crispr therapeutics -stock -share expected interest is significantly higher compared to previous quarter (+62.1%) and same quarter last year (+66.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 0 |
| 2019 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 364 inf% YoY inf% QoQ | 575 inf% YoY 58.0% QoQ |
| 2021 | 686 inf% YoY 19.3% QoQ | 519 inf% YoY -24.3% QoQ | 372 2.2% YoY -28.3% QoQ | 482 -16.2% YoY 29.6% QoQ |
| 2022 | 568 -17.2% YoY 17.8% QoQ | 460 -11.4% YoY -19.0% QoQ | 358 -3.8% YoY -22.2% QoQ | 355 -26.3% YoY -0.8% QoQ |
| 2023 | 443 -22.0% YoY 24.8% QoQ | 468 1.7% YoY 5.6% QoQ | 364 1.7% YoY -22.2% QoQ | 218 -38.6% YoY -40.1% QoQ |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of crispr therapeutics -stock -share was 23.97 per week. The last year interest of crispr therapeutics -stock -share compared to the last 5 years has changed by 38.97%. The interest for crispr therapeutics -stock -share is trending. This didn't exist 5 years ago.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for CRSP
Company name: CRISPR Therapeutics AG
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-10-19T13:05:00-07:00
GlobeNewswire
CRISPR Therapeutics Announces Chief Financial Officer Transition2026-10-15T21:47:13.194523658Z
Analyst Upgrades
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $522026-10-08T05:30:00-07:00
GlobeNewswire
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 20262026-09-14T13:05:00-04:00
Earnings Call Transcripts
CRISPR Tx - 1774369 - CRISPR THERAPEUTICS AG2026-09-08T05:30:00-07:00
GlobeNewswire
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference2026-08-31T12:35:38.345645566Z
Analyst Upgrades
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target2026-08-31T10:03:17.263114369Z
Analyst Upgrades
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target2026-08-28T07:31:00-07:00
GlobeNewswire
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 20262026-08-10T13:07:15-07:00
GlobeNewswire
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors2026-08-04T15:24:40.990142606Z
Analyst Upgrades
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $882026-08-03T13:15:00-07:00
GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results2026-07-08T10:14:28.487988883Z
Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target2026-07-06T12:42:29.546805704Z
Analyst Upgrades
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target2026-05-28T12:00:00Z
GlobeNewswire
CRISPR Therapeutics to Participate in Upcoming Investor Conferences2026-05-13T18:35:53Z
Analyst Upgrades
Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56